Approved indications (U.S.): In adults, Avastin is FDA‑approved in combination with specific chemotherapy or targeted agents for: metastatic colorectal cancer; first‑line, recurrent, or metastatic non‑squamous non‑small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; epithelial ovarian, fallopian tube, or primary peritoneal cancer in certain first‑line, recurrent platinum‑sensitive, and platinum‑resistant settings; and persistent, recurrent, or metastatic cervical cancer.

Off‑label uses: Bevacizumab is widely used off‑label (often as specialized ophthalmic formulations) for eye diseases such as neovascular (wet) age‑related macular degeneration and other retinal vascular disorders, supported by strong clinical trial evidence, but these ophthalmic uses involve different preparation and dosing than systemic Avastin for cancer.

Efficacy expectations: In cancer, responses are usually assessed over weeks to a few months using imaging and clinical evaluation; Avastin tends to improve progression‑free survival and, in some settings, overall survival when added to standard regimens, but it is rarely curative on its own.

Comparison to similar drugs: Compared with other anti‑VEGF or anti‑angiogenic agents (such as ramucirumab or oral tyrosine kinase inhibitors), Avastin has similar goals—slowing tumor growth and spread—but choice depends on cancer type, prior treatments, side‑effect profile, and combination partners.

Typical dosing and administration: Avastin is given only by intravenous infusion in a healthcare setting, usually over 30–90 minutes, at doses commonly ranging from 5 mg/kg every 2 weeks to 15 mg/kg every 3 weeks depending on the specific cancer and regimen; it is often started after or with chemotherapy and continued as maintenance until disease progression or unacceptable toxicity.

Special dosing instructions: Infusion time may be lengthened for the first dose and shortened later if well tolerated; doses may be delayed or reduced, or treatment temporarily stopped, for significant high blood pressure, protein in the urine, surgery, serious bleeding, or other complications, and it is typically held for at least several weeks before and after major surgery to reduce wound‑healing problems.

Missed dose guidance: If an infusion appointment is missed, patients should contact their oncology team promptly to reschedule rather than trying to “make up” the dose on their own.

Overdose: Suspected overdose or significantly excessive dosing is managed in a medical setting with close monitoring and supportive care, focusing on blood pressure, kidney function, and signs of bleeding or other toxicities, since there is no specific antidote.

Common side effects: Frequently reported effects include high blood pressure, fatigue, headache, nosebleeds, diarrhea, decreased appetite, and protein in the urine; these can begin within days to weeks of starting therapy and are often mild to moderate but may require blood pressure medicines or dose adjustments.

Serious or rare adverse effects: Serious risks include gastrointestinal perforation, impaired wound healing and wound complications, severe bleeding (e.g., pulmonary or gastrointestinal), blood clots and arterial thromboembolic events (stroke or heart attack), fistula formation, reversible posterior leukoencephalopathy syndrome, serious hypertension or hypertensive crisis, kidney damage with nephrotic syndrome, and infusion reactions, any of which need immediate medical attention.

Warnings and precautions: Avastin is generally avoided during pregnancy because it can harm the fetus and is usually not recommended while breastfeeding; it is not approved for pediatric cancer indications in the U.S. and requires caution in people with recent surgery, uncontrolled hypertension, history of significant bleeding, serious cardiovascular disease, or kidney impairment.

Safety compared with other drugs: Compared with many cytotoxic chemotherapies, Avastin causes less hair loss or nausea but carries distinctive vascular and wound‑healing risks, so blood pressure, urine protein, and overall cardiovascular status must be monitored regularly.

Side‑effect monitoring and reporting: Patients should promptly report new or worsening headaches, shortness of breath, chest pain, severe abdominal pain, vision or mental changes, unusual bleeding, or sudden swelling; side effects can be reported to the FDA MedWatch program or to the prescribing clinic, and safety updates are periodically published by regulators and the manufacturer.

Drug and treatment interactions: Avastin is not extensively metabolized by liver enzymes, so classic drug–drug interactions are less common, but combining it with other medicines that increase bleeding risk (such as full‑dose anticoagulants or certain anti‑platelet drugs) or with other agents causing high blood pressure or kidney damage can raise the chance of serious side effects; caution is also needed when used with radiation or certain surgeries because of wound‑healing and tissue‑damage concerns.

Foods, alcohol, and supplements: No specific food interactions are known, but alcohol may worsen blood pressure or liver stress from other cancer drugs; herbal supplements that affect bleeding or blood pressure (for example, high‑dose ginkgo, garlic, or ginseng products) should be used cautiously and only after discussion with the oncology team.

Precautions and contraindications: Use may be unsafe or require extra caution in people with recent major surgery, active serious bleeding, uncontrolled hypertension, significant cardiovascular or cerebrovascular disease, bowel inflammation or obstruction, or poor wound healing, and clinicians weigh risks and benefits carefully before starting therapy.

Monitoring needs: Regular monitoring typically includes blood pressure checks, urine tests for protein, kidney function tests, and periodic imaging to assess tumor response; additional tests such as neurological exams or cardiac evaluation may be performed if symptoms suggest complications.

Q: How long do I need to stay on Avastin treatment?
A: Many patients continue Avastin as long as their cancer is controlled and side effects remain manageable, with the oncology team reassessing the benefit and risk at regular intervals.

Q: Will my hair fall out from Avastin?
A: Avastin by itself does not usually cause significant hair loss, but many people receive it with chemotherapy drugs that commonly do, so hair changes depend largely on the overall regimen.

Q: How soon might Avastin start working?
A: Improvement is often evaluated with scans and symptoms over several weeks to a few months, since Avastin works by slowing tumor blood supply rather than providing an immediate effect that you can always feel.

Q: Can I drive after my Avastin infusion?
A: Most people can drive if they feel well, but because fatigue, headache, or infusion reactions can occur, it is often recommended to have someone available to drive you home, especially after early treatments.

Q: Is Avastin chemotherapy or immunotherapy?
A: Avastin is a targeted monoclonal antibody against VEGF (an angiogenesis inhibitor), not a traditional chemotherapy; it is sometimes combined with chemotherapy or immunotherapy to enhance cancer control.

Storage: Avastin vials are stored and handled by healthcare professionals in a clinic, hospital, or infusion center; patients typically do not store this medicine at home.

Disposal: Any unused drug and used IV supplies are disposed of by medical staff as medical and hazardous waste according to healthcare facility procedures, so no special disposal steps are usually required from the patient.